JPWO2020163823A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020163823A5 JPWO2020163823A5 JP2021546264A JP2021546264A JPWO2020163823A5 JP WO2020163823 A5 JPWO2020163823 A5 JP WO2020163823A5 JP 2021546264 A JP2021546264 A JP 2021546264A JP 2021546264 A JP2021546264 A JP 2021546264A JP WO2020163823 A5 JPWO2020163823 A5 JP WO2020163823A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803299P | 2019-02-08 | 2019-02-08 | |
| US62/803,299 | 2019-02-08 | ||
| PCT/US2020/017364 WO2020163823A2 (en) | 2019-02-08 | 2020-02-07 | Therapeutic agents and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520061A JP2022520061A (ja) | 2022-03-28 |
| JPWO2020163823A5 true JPWO2020163823A5 (enExample) | 2023-05-23 |
Family
ID=71948254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546264A Pending JP2022520061A (ja) | 2019-02-08 | 2020-02-07 | 治療薬および治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220169628A1 (enExample) |
| EP (1) | EP3920923A4 (enExample) |
| JP (1) | JP2022520061A (enExample) |
| KR (1) | KR20210137025A (enExample) |
| CN (1) | CN113660937A (enExample) |
| AU (1) | AU2020218367A1 (enExample) |
| CA (1) | CA3127501A1 (enExample) |
| WO (1) | WO2020163823A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115038697A (zh) * | 2020-01-15 | 2022-09-09 | 佛罗里达大学研究基金公司 | 治疗剂和治疗方法 |
| WO2022072094A2 (en) * | 2020-08-28 | 2022-04-07 | University Of Florida Research Foundation, Incorporated | Modulators of nuclear receptor subfamily 4 group a member 1 (nr4a1) and uses thereof |
| KR20230170644A (ko) | 2021-02-02 | 2023-12-19 | 르 라보레또레 쎄르비에르 | 선택적 bcl-xl protac 화합물 및 사용 방법 |
| TW202328122A (zh) | 2021-09-01 | 2023-07-16 | 大陸商四川海思科製藥有限公司 | 降解Bcl-2家族蛋白的化合物及其在醫藥上的應用 |
| US20240398764A1 (en) * | 2021-10-12 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| AU2022405016A1 (en) | 2021-12-09 | 2024-06-06 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
| EP4457225A4 (en) | 2021-12-30 | 2025-09-24 | Beigene Switzerland Gmbh | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH AN E3 LIGASE LIGAND AND METHODS OF USE |
| CN116396288A (zh) * | 2022-01-04 | 2023-07-07 | 上海科技大学 | 基于bcl-2家族蛋白配体化合物开发的蛋白降解剂及它们的应用 |
| JP2025516358A (ja) | 2022-05-06 | 2025-05-27 | ツリーライン バイオサイエンシズ インコーポレイテッド | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 |
| AU2023264537A1 (en) | 2022-05-06 | 2024-11-14 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| CA3251489A1 (en) | 2022-05-06 | 2023-11-09 | Treeline Biosciences, Inc. | BCL-XL HETEROBFUNCTIONAL TETRAHYDROISOQUINOLINE DEGRADING AGENTS |
| CN115028679B (zh) * | 2022-08-11 | 2022-11-15 | 深圳湾实验室 | 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用 |
| CN120659777A (zh) * | 2022-10-03 | 2025-09-16 | 佛罗里达大学研究基金公司 | 募集Cereblon的Bcl-xL/Bcl-2双重降解剂 |
| WO2024078581A1 (en) * | 2022-10-12 | 2024-04-18 | Appicine Therapeutics (Hk) Limited | Selective bcl-xl protac compounds and uses thereof |
| CN120569222A (zh) * | 2023-01-18 | 2025-08-29 | 苏州宜联生物医药有限公司 | 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途 |
| JP2026507476A (ja) * | 2023-02-17 | 2026-03-04 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | トリフルオロメタンスルホニル基を含む化合物 |
| WO2025101575A1 (en) | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| TW202527930A (zh) | 2023-11-07 | 2025-07-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| WO2025101571A1 (en) | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| WO2026015489A1 (en) * | 2024-07-08 | 2026-01-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| MX390189B (es) * | 2015-01-20 | 2025-03-20 | Arvinas Operations Inc | COMPUESTOS Y METODOS PARA LA DEGRADACION DIRIGIDA DE RECEPTOR DE ANDROGENOs. |
| AU2016232705C1 (en) * | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017030814A1 (en) * | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| JP6936498B2 (ja) * | 2016-04-21 | 2021-09-15 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用 |
| ES2989988T3 (es) * | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| CA3045037A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| US20240398764A1 (en) * | 2021-10-12 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| AU2022405016A1 (en) * | 2021-12-09 | 2024-06-06 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
-
2020
- 2020-02-07 WO PCT/US2020/017364 patent/WO2020163823A2/en not_active Ceased
- 2020-02-07 KR KR1020217028572A patent/KR20210137025A/ko not_active Ceased
- 2020-02-07 CN CN202080027337.5A patent/CN113660937A/zh active Pending
- 2020-02-07 US US17/429,207 patent/US20220169628A1/en active Pending
- 2020-02-07 CA CA3127501A patent/CA3127501A1/en active Pending
- 2020-02-07 AU AU2020218367A patent/AU2020218367A1/en not_active Abandoned
- 2020-02-07 EP EP20753239.1A patent/EP3920923A4/en not_active Withdrawn
- 2020-02-07 JP JP2021546264A patent/JP2022520061A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020163823A5 (enExample) | ||
| JP2007534730A (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| JP2013231086A (ja) | 化学療法の強化方法 | |
| JP2006523216A5 (enExample) | ||
| JP2005533748A5 (enExample) | ||
| WO2010031265A1 (zh) | 用于治疗增生性疾病的药物组合物 | |
| CN111902147A (zh) | 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗 | |
| JP2005508857A5 (enExample) | ||
| BR112020022654A2 (pt) | Composições de combinação que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso das mesmas | |
| CN1283248C (zh) | 包含埃坡霉素的组合及其药学应用 | |
| JP2009536956A (ja) | 抗癌治療法 | |
| CN1511036A (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| US6355628B1 (en) | Combination therapy using pentafluorobenzenesulfonamides | |
| JPWO2022182857A5 (enExample) | ||
| EA006295B1 (ru) | Применение производных дистамицина для противоопухолевой терапии | |
| US6822001B2 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
| JP2002326936A (ja) | 腫瘍転移および癌の治療における５−フルオロウラシルの有効性の増強 | |
| JP2005510471A (ja) | 減少した毒性のシスプラチン製剤及びそれを使用する方法 | |
| JPWO2023107606A5 (enExample) | ||
| CN1302777C (zh) | 包括取代的丙烯酰偏端霉素衍生物和放射治疗的抗肿瘤联合疗法 | |
| JP2003535874A5 (enExample) | ||
| JP2005516025A (ja) | 置換されたアクリロイルジスタマイシン誘導体およびプロテインキナーゼ（セリン／トレオニンキナーゼ）インヒビターを含む、腫瘍に対する併用療法 | |
| CZ20024107A3 (cs) | Farmaceutický prostředek obsahující farmaceuticky přijatelný nosič nebo masťový základ a jako aktivní přísadu derivát akryloyldistamycinu a antimikrotubulové činidlo a/nebo antimetabolit | |
| WO2009139085A1 (ja) | 抗腫瘍剤、キット及び癌治療方法 | |
| HK40040206A (en) | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |